ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,495.20
0.56%
S&P ASX All Technology
4,017.00
1.28%
Brent Oil
73.68
2.49%
US Dollar vs AUD
1.54059
-0.26%
Bitcoin
95,340.63
-0.54%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. TransMedics Group Inc (TMDX)

  7. TransMedics Group Inc (TMDX) News

TransMedics Group Inc

TransMedics Group Inc (TMDX)

NASDAQ
72.23
-12.91
( -15.16% )
Updated: 05:48:44
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

TMDX News

Official News Only

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
21 hours ago
TMDX (-15.16%)

Form 8-K - Current report
Edgar (US Regulatory)
22 hours ago
TMDX (-15.16%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 November 2024
TMDX (-15.16%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
06 November 2024
TMDX (-15.16%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
30 October 2024
TMDX (-15.16%)

Form 8-K - Current report
Edgar (US Regulatory)
29 October 2024
TMDX (-15.16%)

TMDX Discussion

View Posts
Monksdream Monksdream 7 months ago
TMDX new 52+ week high
👍️0
Monksdream Monksdream 9 months ago
TMDX 10Q
👍️0
make it happen make it happen 1 year ago
Should touch $50 net lose widens, and has a 40% day. The structure shows over 100% ownership which technically should be illegal. How can there be over 100%? Imho mean institutions and whomever will be selling for a 40%ish profit overnight.
👍️0
crudeoil24 crudeoil24 4 years ago
TransMedics Late Tuesday Announced FDA Advisory Committee Panel Voted 12 To 5 That Benefits Of OCS Heart System Outweigh Risks
6:58 am ET April 7, 2021 (Benzinga) Print
TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after the review of TransMedics' clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol ("CAP") results, as well as the OCS Heart PROCEED II trial, the Circulatory Systems Device Advisory Panel convened by the U.S. Food and Drug Administration ("FDA") has issued a favorable vote in support of approval of the OCS Heart System to the FDA's Office of Health Technology 2 (Cardiovascular Devices). The panel voted 12 to 5, with 1 abstaining, that the benefits of the OCS Heart System outweigh its risks. The panel voted 10 to 6, with 2 abstaining, that there is reasonable assurance that the OCS Heart System is effective. The panel voted 9 to 7, with 2 abstaining, that there is reasonable assurance of the OCS Heart System's safety.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
👍️0
crudeoil24 crudeoil24 4 years ago
Transmedics group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Lung INSPIRE Trial, OCS Lung Expand Trial, OCs Heart EXPAND and PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. It is also focused on developing additional OCS products for kidney transplantation.
👍️0

Your Recent History

NASDAQ
TMDX
TransMedics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved